Table 3.

Magnetic resonance imaging (MRI) results at hospital discharge and at four months.

	Ivabradine	Placebo	p
MRI at hospital discharge
Infarct size (g)	13.7 (5.1;24.3)	22.1 (12.0;29.9)
Number of patients	24	13
E (SE) (95% CI)	−7.5 (4.4) (−16.4–1.5)		0.103
Relative infarct size (% of LV mass)	11.7 (4.3;16.5)	18.1 (12.5;21.1)
Number of patients	24	13
E (SE) (95% CI)	−4.6 (3.4) (−11.4–2.3)		0.190
Area at risk (% of LV mass)	24.4 (18.5;38.8)	31.4 (23.0;39.4)
Number of patients	15	10
E (SE) (95% CI)	1.0 (6.5) (−12.4–14.4)		0.879
Microvascular obstruction (g)	4.1 (1.6;6.1)	5.2 (1.8;7.1)
Number of patients	8	6
E (SE) (95% CI)	−2.6 (2.9) (−8.8–3.7)		0.315
Microvascular obstruction (% of LV mass)	2.8 (1.3;5.8)	4.0 (1.7;4.6)
Number of patients	8	6
E (SE) (95% CI)	−0.9 (1.9) (−5.1–3.3)		0.617
MRI at four months follow up
Infarct size (g)	8.7 (2.7;16.8)	6.3 (5.1;18.7)
Number of patients	24	12
E (SE) (95% CI)	−1.2 (3.1) (−7.5–5.2)		0.726
Relative infarct size (% of LV mass)	7.5 (2.5;17.6)	5.8 (4.9;14.6)
Number of patients	24	12
E (SE) (95% CI)	0.2 (2.9) (−5.8–6.2)		0.945

CI: confidence interval; E: estimate; LV: left ventricular; SE: standard error.

Values are median (Q1;Q3) unless otherwise indicated.